Abstract

Rupali Yevale* and Dr. Vikas Jain

ABSTRACT

Now a day Hyperglycaemia (type 2 diabetes) is a major therapeutic problem. This is moderately because reduced insulin sensitivity and beta cell failure lead to resistant to current therapies. The thiazolidinediones are a new class of drugs that get better insulin sensitivity. Thiazolidinedione structure has been an significant structural domain of research, involving design and development of new drugs for the treatment of type 2 diabetes. Wide research on the mechanism of action and the structural requirements has shown that the intended antidiabetic activity in type 2 diabetes is due to their agonistic effect on peroxisome proliferator-activated receptor (PPAR) belonging to the nuclear receptor super family. Pharmacology and chemistry of thiazolidinediones as PPAR???? agonists and the potential of newer analogues as dual agonists of PPARs and other promising targets for the therapy of type 2 diabetes are presented. Thiazolidinediones (TZDs) are five-membered heterocyclic having sulfur, nitrogen, and oxygen atoms in their ring structure and exhibiting potent as well as wide range of pharmacological activities.